According to Ionis Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.78 B. In 2022 the company made a revenue of $0.58 B a decrease over the years 2021 revenue that were of $0.81 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.78 B | 34.1% |
2022 | $0.58 B | -27.53% |
2021 | $0.81 B | 11.13% |
2020 | $0.72 B | -35.04% |
2019 | $1.12 B | 87.2% |
2018 | $0.59 B | 15.61% |
2017 | $0.51 B | 49.64% |
2016 | $0.34 B | 22.18% |
2015 | $0.28 B | 32.47% |
2014 | $0.21 B | 45.4% |
2013 | $0.14 B | 44.33% |
2012 | $0.10 B | 2.99% |
2011 | $99.08 M | -8.65% |
2010 | $0.10 B | -10.8% |
2009 | $0.12 B | 23.83% |
2008 | $98.2 M | 41.05% |
2007 | $69.62 M | 183.81% |
2006 | $24.53 M | -38.88% |
2005 | $40.13 M | -5.84% |
2004 | $42.62 M | -14.73% |
2003 | $49.98 M | -37.65% |
2002 | $80.17 M | 50.51% |
2001 | $53.27 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | -81.14% | ๐บ๐ธ USA |